Efficacy And Safety of Glimpride in Type 2 Diabetes Patients in Eastern Libya
DOI:
https://doi.org/10.58987/1zte5k85Keywords:
Glimepiride, Type 2 diabetes, T2DM Treatment, Diabetes TreatmentAbstract
Glimepiride is a drug used in the treatment of type 2 diabetes and can be combined with metformin, another anti-hyperglycemic agent, for patients with difficulty controlling their blood sugar levels. Study Timeframe: This study was conducted during 2023–2024. The study consisted of two parts, the first of which includes the theoretical computer framework, which dealt with the advanced study of some information related to the subject of the study, and the second is the procedural aspect or computer construction, in which the study group used a study form to fill in the data, and then it was statistically analyzed and its results were commented on. The spatial boundaries were represented in the outpatient clinics of the National Center for Diabetes and Endocrinology, eastern Libya (Al-marj – Benghazi – Al-Abyar). The sample consisted of 150 patients with type 2 diabetes (56 males – 94 females), aged between 32–90 years, selected based on initial hemoglobin and fasting plasma glucose measurements. Most received Glimepiride in combination with Metformin. The study concluded that Glimepiride is safe with no observed side effects and improved blood sugar control in patients, as well as hemoglobin and fasting plasma glucose levels.
References
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
1. Retention of Rights: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).
2. User Rights: This license allows others to remix, tweak, and build upon the work non-commercially, and although their new works must also acknowledge the original author and be non-commercial, they do not have to license their derivative works on the same terms.
3. Restrictions: The material cannot be used for commercial purposes without prior written permission from the author or the journal.
4. Additional Agreements: Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository), with an acknowledgement of its initial publication in this journal.
